Insider Buying: MBX Biosciences, Inc. (NYSE:MBX) Director Acquires 143,170 Shares of Stock

MBX Biosciences, Inc. (NYSE:MBX) Director Carl L. Gordon purchased 143,170 shares of MBX Biosciences stock in a transaction that occurred on Tuesday, February 18th. The stock was acquired at an average cost of $10.84 per share, with a total value of $1,551,962.80. Following the transaction, the director now owns 3,255,000 shares in the company, valued at $35,284,200. This trade represents a 4.60 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

MBX Biosciences Trading Down 8.0 %

MBX opened at $10.88 on Friday. The business’s fifty day moving average price is $14.05. MBX Biosciences, Inc. has a 1 year low of $8.63 and a 1 year high of $27.50.

Hedge Funds Weigh In On MBX Biosciences

A number of hedge funds have recently bought and sold shares of MBX. The Manufacturers Life Insurance Company purchased a new position in MBX Biosciences during the 3rd quarter worth $1,200,000. NEA Management Company LLC purchased a new position in MBX Biosciences during the 3rd quarter worth $93,904,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in MBX Biosciences during the 3rd quarter worth $278,000. Maven Securities LTD purchased a new position in MBX Biosciences during the 3rd quarter worth $1,299,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of MBX Biosciences in the 3rd quarter worth about $405,000.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.